


L-Homocysteic acid

Cat. No.:	HY-138903
CAS No.:	14857-77-3
Molecular Formula:	C ₄ H ₉ NO ₅ S
Molecular Weight:	183.18
Target:	iGluR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	L-Homocysteic acid (L-HCA) is an endogenous excitatory amino acid that acts as a NMDA receptor agonist (EC ₅₀ : 14 μM). L-Homocysteic acid is neurotoxic, and can be used in the research of neurological disorders ^{[1][2][3]} .								
IC₅₀ & Target	NMDA Receptor 14 μM (EC ₅₀)								
In Vitro	L-Homocysteic acid activates NMDA receptor with an EC ₅₀ value of 14 μM ^[1] . L-Homocysteic acid (100 μM) induces large currents (1.8 nA) that is insensitive to the NMDA receptor-antagonist mixture in Purkinje cells ^[1] . L-Homocysteic acid (250 μM, 30 min) potently induces an acute excitotoxic reaction in ex vivo chick embryo retina ^[2] . L-Homocysteic acid (0-2 mM, 48 h) induces a concentration-dependent neurotoxic effect in rat primary neurons ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	L-Homocysteic acid (intraperitoneal injection, 4-11 mmol/kg) elicits seizures in rats during early postnatal development ^[4] . L-Homocysteic acid (intraperitoneal injection, 100-1500 mg/kg) partially substitutes for NMDA, producing maximum values of 61-67% NMDA-lever responding at doses of 1000 and 560 mg/kg, respectively in Sprague-Dawley rats ^[5] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
	<table border="1"> <tr> <td>Animal Model:</td> <td>Male albino rats of the Wistar strain^[4]</td> </tr> <tr> <td>Dosage:</td> <td>4, 5.5, 8, 11 mM/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection, daily for 14 days</td> </tr> <tr> <td>Result:</td> <td>Induced flexion seizures at 4 mmol/kg. Led to intense tail flicking, pivoting, and locomotion. Decreased ECoG (electrocorticograms) activity for 5-9 min.</td> </tr> </table>	Animal Model:	Male albino rats of the Wistar strain ^[4]	Dosage:	4, 5.5, 8, 11 mM/kg	Administration:	Intraperitoneal injection, daily for 14 days	Result:	Induced flexion seizures at 4 mmol/kg. Led to intense tail flicking, pivoting, and locomotion. Decreased ECoG (electrocorticograms) activity for 5-9 min.
Animal Model:	Male albino rats of the Wistar strain ^[4]								
Dosage:	4, 5.5, 8, 11 mM/kg								
Administration:	Intraperitoneal injection, daily for 14 days								
Result:	Induced flexion seizures at 4 mmol/kg. Led to intense tail flicking, pivoting, and locomotion. Decreased ECoG (electrocorticograms) activity for 5-9 min.								

REFERENCES

[1]. M Yuzaki, et al. Characterization of L-homocysteate-induced currents in Purkinje cells from wild-type and NMDA receptor knockout mice. J Neurophysiol . 1999 Nov;82(5):2820-6.

[2]. J W Olney, et al. L-homocysteic acid: an endogenous excitotoxic ligand of the NMDA receptor. Brain Res Bull. 1987 Nov;19(5):597-602.

[3]. B Lockhart, et al. Inhibition of L-homocysteic acid and buthionine sulphoximine-mediated neurotoxicity in rat embryonic neuronal cultures with alpha-lipoic acid enantiomers. Brain Res. 2000 Feb 14;855(2):292-7.

[4]. P Mares, et al. Convulsant action of D,L-homocysteic acid and its stereoisomers in immature rats.

[5]. Katherine L Nicholson, et al. The discriminative stimulus effects of N-methyl-D-aspartate glycine-site ligands in NMDA antagonist-trained rats. Psychopharmacology (Berl). 2009 Apr;203(2):441-51.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA